GSK plc (GSK)
| Previous close | 42.57 |
| Open | 42.90 |
| Bid | 43.22 x 1200 |
| Ask | 43.22 x 1000 |
| Day's range | 42.75 - 43.25 |
| 52-week range | 33.33 - 43.84 |
| Volume | |
| Avg. volume | 3,445,390 |
| Market cap | 88.064B |
| Beta (5Y monthly) | 0.27 |
| PE ratio (TTM) | 15.82 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 1.47 (3.45%) |
| Ex-dividend date | 16 May 2024 |
| 1y target est | N/A |
- Business Wire
Positive RUBY phase III data show potential for Jemperli (dostarlimab-gxly) combinations in more patients with primary advanced or recurrent endometrial cancer
PHILADELPHIA, March 16, 2024--RUBY phase III data show potential for Jemperli (dostarlimab-gxly) combinations in more patients with primary advanced or recurrent endometrial cancer
- Business Wire
GSK Doubles COiMMUNITY Grant Funding, Launches Patient Resources, as Adult Vaccination Rates Begin to Show Promising Rise
PHILADELPHIA, March 07, 2024--GSK doubles COiMMUNITY grant funding, launches patient resources, as adult vaccination rates begin to show promising rise
- GlobeNewswire
Alector Announces First Patient Dosed in PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Patients with Early Alzheimer’s Disease
The trial, being conducted in partnership with GSK, is expected to enroll approximately 282 patients globallySOUTH SAN FRANCISCO, Calif., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC) and GSK plc (LSE/NYSE: GSK) today announced that the first patient has been dosed in PROGRESS-AD, the global Phase 2 clinical trial of AL101/GSK4527226 in patients with early Alzheimer’s disease (AD), including mild cognitive impairment and mild dementia due to AD. AL101 is an investigational human
